Consumer confidence is breaking down in a way investors have not seen in years. The University of Michigan Consumer Sentiment Index landed at 53.3 in March 2026, sitting below the 60 recessionary threshold, and the latest Surveys of Consumers reading dropped further to 49.8 in April 2026, a 6.6% month-over-month decline matching the trough from June 2022. With year-ahead inflation expectations jumping to 4.7%, the playbook history tends to favor is defensive: healthcare names that sell into non-discretionary demand and consumer staples brands with pricing power and dividend track records.
With that backdrop in mind, here are three stocks trading under $25 that fit the healthcare and consumer staples defensive mold and that analysts see as worth a closer look right now.
AdaptHealth (NASDAQ: AHCO)
AdaptHealth (NASDAQ:AHCO) is a home medical equipment provider focused on sleep, respiratory, diabetes, and wellness care. Shares closed at $11.75, leaving plenty of headroom under the $25 ceiling for retail investors building a defensive sleeve. The stock is up 35.06% over the past year, even after a rough Q4 in which revenue of $846.29M missed badly and EPS came in at -$0.76 on a $128M goodwill impairment. Analysts still tilt bullish: one strong buy, five buys, and two holds, with a $13.19 price target and a forward P/E of 13x.
The bull case rests on the largest capitated contract in HME industry history covering roughly 170,000 members, plus $225M of debt repaid year to date through Q3 and FY2026 guidance of $3.44B to $3.51B in revenue with $680M to $730M in adjusted EBITDA. The risk is execution on that contract ramp after the Q4 miss. For investors hunting an inexpensive, recurring-revenue healthcare name, AdaptHealth offers a credible recovery story.
Bioventus (NASDAQ: BVS)
Bioventus (NASDAQ:BVS) is a medical device maker covering knee osteoarthritis pain treatments, surgical bone graft solutions, and EXOGEN bone stimulation. Shares trade at $10.68 after rallying 51.92% over the past year. Q4 revenue of $157.9M grew 2.8% and beat consensus, with organic growth of 10.0% and adjusted EPS of $0.24. Analyst coverage skews aggressively bullish: two strong buys and three buys with no holds or sells, an analyst target of $14.80, and a forward P/E of 13x.
FY2026 guidance calls for net sales of $600M to $610M and adjusted EPS of $0.73 to $0.77, supported by gross margins above 68% and a non-opioid chronic pain pipeline launching StimTrial and TalisMann. The risk is product concentration and potential FDA reclassification of EXOGEN. Bioventus pairs healthcare defensiveness with a real growth angle that few sub-$15 medtech names can match.
Hormel Foods (NYSE: HRL)
Hormel Foods (NYSE:HRL | HRL Price Prediction) owns SPAM, Planters, Skippy, Jennie-O, Applegate, and Columbus, the kind of pantry brands that hold up when wallets tighten. The stock sits at $20.93, comfortably under $25 after a 24.77% one-year decline. Q1 FY2026 delivered adjusted EPS of $0.34, beating consensus of $0.32, marking the fifth consecutive quarter of organic net sales growth. Foodservice revenue rose 7.3% with segment profit up 13%, the 10th straight quarter of organic growth there.
The headline draw is income: a 5.45% dividend yield backed by 60 consecutive years of dividend increases, putting Hormel firmly in Dividend King territory. Reaffirmed FY2026 guidance points to adjusted EPS of $1.43 to $1.51, growth of 4% to 10%, and the analyst target sits at $26.75 on a forward P/E of 15x. Retail segment weakness, with profit down 19%, and commodity input inflation are the live risks. For income-oriented portfolios looking for ballast, Hormel checks the staples box.
Read the filings, weigh the risks against your own time horizon, and do your own research before acting.
Top Gaining Stocks
Top Losing Stocks